Immunotherapeutic organoids

References

• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 7; http://dx.doi.org/10.1038/256495a0; PMID: 1172191
   PubMed Web of Science ®Google Scholar
• Sanz L, Cuesta AM, Compte M, Álvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005; 26:641 - 8; http://dx.doi.org/10.1111/j.1745-7254.2005.00135.x; PMID: 15916728
   PubMed Web of Science ®Google Scholar
• Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Álvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010; 28:355 - 62; http://dx.doi.org/10.1016/j.tibtech.2010.03.007; PMID: 20447706
   PubMed Web of Science ®Google Scholar
• Sanz L, Blanco B, Álvarez-Vallina L. Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks. Trends Immunol 2004; 25:85 - 91; http://dx.doi.org/10.1016/j.it.2003.12.001; PMID: 15102367
   PubMed Web of Science ®Google Scholar
• Noël D, Pelegrin M, Marin M, Biard-Piechaczyk M, Ourlin JC, Mani JC, et al. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum Gene Ther 1997; 8:1219 - 29; http://dx.doi.org/10.1089/hum.1997.8.10-1219; PMID: 9215739
   PubMed Web of Science ®Google Scholar
• Noël D, Pelegrin M, Kramer S, Jacquet C, Skander N, Piechaczyk M. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther 2002; 13:1483 - 93; http://dx.doi.org/10.1089/10430340260185111; PMID: 12215269
   PubMed Web of Science ®Google Scholar
• Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003; 10:955 - 63; http://dx.doi.org/10.1038/sj.gt.3302037; PMID: 12756416
   PubMed Web of Science ®Google Scholar
• Xiao PJ, Lentz TB, Samulski RJ. Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector. Ther Deliv 2012; 3:835 - 56; http://dx.doi.org/10.4155/tde.12.63; PMID: 22900466
   PubMedGoogle Scholar
• Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23:584 - 90; http://dx.doi.org/10.1038/nbt1087; PMID: 15834403
   PubMed Web of Science ®Google Scholar
• Watanabe M, Boyer JL, Crystal RG. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther 2009; 20:598 - 610; http://dx.doi.org/10.1089/hum.2008.169; PMID: 19254174
   PubMed Web of Science ®Google Scholar
• Ho DT, Wykoff-Clary S, Gross CS, Schneider D, Jin F, Kretschmer PJ, et al. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther 2009; 16:184 - 94; http://dx.doi.org/10.1038/cgt.2008.68; PMID: 18758433
   PubMed Web of Science ®Google Scholar
• Wang G, Qiu J, Wang R, Krause A, Boyer JL, Hackett NR, et al. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 2010; 17:559 - 70; http://dx.doi.org/10.1038/cgt.2010.11; PMID: 20448672
   PubMed Web of Science ®Google Scholar
• Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C, et al. “Active” cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res 2008; 68:9176 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-08-1688; PMID: 19010889
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81 - 4; http://dx.doi.org/10.1038/nature10660; PMID: 22139420
   PubMed Web of Science ®Google Scholar
• Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther 2002; 9:256 - 62; http://dx.doi.org/10.1038/sj.gt.3301639; PMID: 11896464
   PubMed Web of Science ®Google Scholar
• Sanz L, Kristensen P, Russell SJ, Ramirez García JR, Alvarez-Vallina L. Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother 2001; 50:557 - 65; http://dx.doi.org/10.1007/s00262-001-0235-5; PMID: 11776378
   PubMed Web of Science ®Google Scholar
• Sanz L, García-Bermejo L, Blanco FJ, Kristensen P, Feijóo M, Suárez E, et al. A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J 2003; 22:1508 - 17; http://dx.doi.org/10.1093/emboj/cdg150; PMID: 12660158
   PubMed Web of Science ®Google Scholar
• Sanz L, Kristensen P, Blanco B, Facteau S, Russell SJ, Winter G, et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther 2002; 9:1049 - 53; http://dx.doi.org/10.1038/sj.gt.3301725; PMID: 12101437
   PubMed Web of Science ®Google Scholar
• Sánchez-Arévalo Lobo VJ, Cuesta AM, Sanz L, Compte M, García P, Prieto J, et al. Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer 2006; 119:455 - 62; http://dx.doi.org/10.1002/ijc.21851; PMID: 16477626
   PubMed Web of Science ®Google Scholar
• Afanasieva TA, Wittmer M, Vitaliti A, Ajmo M, Neri D, Klemenz R. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther 2003; 10:1850 - 9; http://dx.doi.org/10.1038/sj.gt.3302085; PMID: 12960975
   PubMed Web of Science ®Google Scholar
• Liu X, Wu J, Zhang S, Li C, Huang Q. Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. Cancer Gene Ther 2009; 16:861 - 72; http://dx.doi.org/10.1038/cgt.2009.30; PMID: 19461676
   PubMed Web of Science ®Google Scholar
• Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:4 - 14; PMID: 22327426
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118 - 29; http://dx.doi.org/10.1038/35101072; PMID: 11905803
   PubMed Web of Science ®Google Scholar
• Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010; 24:89 - 98; http://dx.doi.org/10.2165/11530960-000000000-00000; PMID: 20199124
   PubMed Web of Science ®Google Scholar
• Dhimolea E, Reichert JM. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs 2012; 4:4 - 13; http://dx.doi.org/10.4161/mabs.4.1.18821; PMID: 22327426
   PubMedGoogle Scholar
• Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010; 2:129 - 36; http://dx.doi.org/10.4161/mabs.2.2.11221; PMID: 20190561
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974 - 7; http://dx.doi.org/10.1126/science.1158545; PMID: 18703743
   PubMed Web of Science ®Google Scholar
• Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?. MAbs 2009; 1:539 - 47; http://dx.doi.org/10.4161/mabs.1.6.10015; PMID: 20073127
   PubMed Web of Science ®Google Scholar
• Blanco B, Holliger P, Vile RG, Álvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171:1070 - 7; PMID: 12847281
   PubMed Web of Science ®Google Scholar
• Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A, et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14:380 - 8; http://dx.doi.org/10.1038/sj.cgt.7701021; PMID: 17218946
   PubMed Web of Science ®Google Scholar
• Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008; 68:9614 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-08-0451; PMID: 19047138
   PubMed Web of Science ®Google Scholar
• Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 2009; 106:4822 - 7; http://dx.doi.org/10.1073/pnas.0806647106; PMID: 19264968
   PubMed Web of Science ®Google Scholar
• Bexell D, Scheding S, Bengzon J. Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 2010; 18:1067 - 75; http://dx.doi.org/10.1038/mt.2010.58; PMID: 20407426
   PubMed Web of Science ®Google Scholar
• Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, Schmoll HJ. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med 2010; 14:2292 - 304; http://dx.doi.org/10.1111/j.1582-4934.2009.00794.x; PMID: 19508388
   PubMed Web of Science ®Google Scholar
• Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62:3603 - 8; PMID: 12097260
   PubMed Web of Science ®Google Scholar
• Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008; 15:1446 - 53; http://dx.doi.org/10.1038/gt.2008.101; PMID: 18596829
   PubMed Web of Science ®Google Scholar
• Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008; 16:749 - 56; http://dx.doi.org/10.1038/mt.2008.3; PMID: 18362930
   PubMed Web of Science ®Google Scholar
• Harting MT, Jimenez F, Xue H, Fischer UM, Baumgartner J, Dash PK, et al. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 2009; 110:1189 - 97; http://dx.doi.org/10.3171/2008.9.JNS08158; PMID: 19301973
   PubMed Web of Science ®Google Scholar
• Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W. LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res 2012; 72:2980 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-11-4216; PMID: 22511579
   PubMed Web of Science ®Google Scholar
• Compte M, Cuesta AM, Sánchez-Martín D, Alonso-Camino V, Vicario JL, Sanz L, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009; 27:753 - 60; http://dx.doi.org/10.1634/stemcells.2008-0831; PMID: 19096041
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557 - 63; http://dx.doi.org/10.1038/nature06188; PMID: 17914389
   PubMed Web of Science ®Google Scholar
• Eliopoulos N, Gagnon RF, Francois M, Galipeau J. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol 2006; 17:1576 - 84; http://dx.doi.org/10.1681/ASN.2005101035; PMID: 16672321
   PubMed Web of Science ®Google Scholar
• Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J, et al. Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol Ther 2009; 17:1241 - 9; http://dx.doi.org/10.1038/mt.2009.82; PMID: 19367255
   PubMed Web of Science ®Google Scholar
• Campeau PM, Rafei M, François M, Birman E, Forner KA, Galipeau J. Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther 2009; 17:369 - 72; http://dx.doi.org/10.1038/mt.2008.270; PMID: 19088705
   PubMed Web of Science ®Google Scholar
• Xin H, Kanehira M, Mizuguchi H, Hayakawa T, Kikuchi T, Nukiwa T, et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007; 25:1618 - 26; http://dx.doi.org/10.1634/stemcells.2006-0461; PMID: 17412895
   PubMed Web of Science ®Google Scholar
• Xin H, Sun R, Kanehira M, Takahata T, Itoh J, Mizuguchi H, et al. Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med 2009; 15:321 - 7; http://dx.doi.org/10.2119/molmed.2009.00059; PMID: 19603106
   PubMed Web of Science ®Google Scholar
• Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008; 26:2332 - 8; http://dx.doi.org/10.1634/stemcells.2008-0084; PMID: 18617688
   PubMed Web of Science ®Google Scholar
• Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65:3307 - 18; PMID: 15833864
   PubMed Web of Science ®Google Scholar
• Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004; 96:1593 - 603; http://dx.doi.org/10.1093/jnci/djh299; PMID: 15523088
   PubMed Web of Science ®Google Scholar
• Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther 2007; 14:828 - 35; http://dx.doi.org/10.1038/sj.cgt.7701077; PMID: 17599089
   PubMed Web of Science ®Google Scholar
• Matsuzuka T, Rachakatla RS, Doi C, Maurya DK, Ohta N, Kawabata A, et al. Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer 2010; 70:28 - 36; http://dx.doi.org/10.1016/j.lungcan.2010.01.003; PMID: 20138387
   PubMed Web of Science ®Google Scholar
• Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010; 12:615 - 25; http://dx.doi.org/10.3109/14653241003631815; PMID: 20230221
   PubMed Web of Science ®Google Scholar
• Seo KW, Lee HW, Oh YI, Ahn JO, Koh YR, Oh SH, et al. Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model. Cytotherapy 2011; 13:944 - 55; http://dx.doi.org/10.3109/14653249.2011.584864; PMID: 21846298
   PubMed Web of Science ®Google Scholar
• Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11:1155 - 64; http://dx.doi.org/10.1038/sj.gt.3302276; PMID: 15141157
   PubMed Web of Science ®Google Scholar
• Gunnarsson S, Bexell D, Svensson A, Siesjö P, Darabi A, Bengzon J. Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma. J Neuroimmunol 2010; 218:140 - 4; http://dx.doi.org/10.1016/j.jneuroim.2009.10.017; PMID: 19914721
   PubMed Web of Science ®Google Scholar
• Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006; 15:865 - 74; http://dx.doi.org/10.1111/j.1600-0625.2006.00479.x; PMID: 17002683
   PubMed Web of Science ®Google Scholar
• Hong X, Miller C, Savant-Bhonsale S, Kalkanis SN. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 2009; 64:1139 - 46, discussion 1146-7; http://dx.doi.org/10.1227/01.NEU.0000345646.85472.EA; PMID: 19487894
   PubMed Web of Science ®Google Scholar
• Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008; 16:749 - 56; http://dx.doi.org/10.1038/mt.2008.3; PMID: 18362930
   PubMed Web of Science ®Google Scholar
• Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 2009; 115:13 - 22; http://dx.doi.org/10.1002/cncr.24013; PMID: 19051291
   PubMed Web of Science ®Google Scholar
• Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169:12 - 20; http://dx.doi.org/10.1159/000047856; PMID: 11340257
   PubMed Web of Science ®Google Scholar
• Ryu CH, Park SH, Park SA, Kim SM, Lim JY, Jeong CH, et al. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther 2011; 22:733 - 43; http://dx.doi.org/10.1089/hum.2010.187; PMID: 21261460
   PubMed Web of Science ®Google Scholar
• Xu G, Jiang XD, Xu Y, Zhang J, Huang FH, Chen ZZ, et al. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 2009; 33:466 - 74; http://dx.doi.org/10.1016/j.cellbi.2008.07.023; PMID: 18725309
   PubMed Web of Science ®Google Scholar
• Hu M, Yang JL, Teng H, Jia YQ, Wang R, Zhang XW, et al. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. BMC Cancer 2008; 8:306.:306.
   Google Scholar
• Mao W, Zhu X, Tang D, Zhao Y, Zhao B, Ma G, et al. TNF-α expression in the UCB-MSCs as stable source inhibits gastric cancers growth in nude mice. Cancer Invest 2012; 30:463 - 72; http://dx.doi.org/10.3109/07357907.2012.675385; PMID: 22536934
   PubMed Web of Science ®Google Scholar
• Menon LG, Kelly K, Yang HW, Kim SK, Black PM, Carroll RS. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009; 27:2320 - 30; http://dx.doi.org/10.1002/stem.136; PMID: 19544410
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69:4134 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-08-4698; PMID: 19435900
   PubMed Web of Science ®Google Scholar
• Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010; 70:3718 - 29; http://dx.doi.org/10.1158/0008-5472.CAN-09-1865; PMID: 20388793
   PubMed Web of Science ®Google Scholar
• Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, Fulda S, et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 2010; 28:2109 - 20; http://dx.doi.org/10.1002/stem.533; PMID: 20882532
   PubMed Web of Science ®Google Scholar
• Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010; 28:2217 - 28; http://dx.doi.org/10.1002/stem.543; PMID: 20945331
   PubMed Web of Science ®Google Scholar
• Mueller LP, Luetzkendorf J, Widder M, Nerger K, Caysa H, Mueller T. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 2011; 18:229 - 39; http://dx.doi.org/10.1038/cgt.2010.68; PMID: 21037557
   PubMed Web of Science ®Google Scholar
• Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY, et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol 2011; 13:61 - 9; http://dx.doi.org/10.1093/neuonc/noq147; PMID: 21062796
   PubMed Web of Science ®Google Scholar
• Kim SM, Woo JS, Jeong CH, Ryu CH, Lim JY, Jeun SS. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res 2012; 72:4807 - 17; http://dx.doi.org/10.1158/0008-5472.CAN-12-0123; PMID: 22962275
   PubMed Web of Science ®Google Scholar
• Zhu X, Su D, Xuan S, Ma G, Dai Z, Liu T, et al. Gene therapy of gastric cancer using LIGHT-secreting human umbilical cord blood-derived mesenchymal stem cells. Gastric Cancer 2012 ; In press http://dx.doi.org/10.1007/s10120-012-0166-1; PMID: 22850801
   PubMed Web of Science ®Google Scholar
• Stagg J, Lejeune L, Paquin A, Galipeau J. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 2004; 15:597 - 608; http://dx.doi.org/10.1089/104303404323142042; PMID: 15212718
   PubMed Web of Science ®Google Scholar
• Eliopoulos N, Francois M, Boivin MN, Martineau D, Galipeau J. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 2008; 68:4810 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-08-0160; PMID: 18559528
   PubMed Web of Science ®Google Scholar
• Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011; 18:488 - 95; http://dx.doi.org/10.1038/gt.2010.170; PMID: 21228885
   PubMed Web of Science ®Google Scholar
• Goren A, Dahan N, Goren E, Baruch L, Machluf M. Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy. FASEB J 2010; 24:22 - 31; http://dx.doi.org/10.1096/fj.09-131888; PMID: 19726759
   PubMed Web of Science ®Google Scholar
• Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, et al. Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer 2012; 15:273 - 82; http://dx.doi.org/10.4048/jbc.2012.15.3.273; PMID: 23091539
   PubMed Web of Science ®Google Scholar
• Balazs AB, West AP Jr.. Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol 2013; 14:1 - 5; http://dx.doi.org/10.1038/ni.2480; PMID: 23238748
   PubMedGoogle Scholar
• Acarregui A, Murua A, Pedraz JL, Orive G, Hernández RM. A perspective on bioactive cell microencapsulation. BioDrugs 2012; 26:283 - 301; PMID: 22715813
   PubMed Web of Science ®Google Scholar